Blackbelt Renaissance Project-Powerpoint-Stegall-Master Thesis
Joseph P. Grande, M.D., Ph.D. Mark D. Stegall, M.D. Walter D. Park
description
Transcript of Joseph P. Grande, M.D., Ph.D. Mark D. Stegall, M.D. Walter D. Park
Accommodation in ABO-Incompatible Kidney Allografts: Graft Self-Protection
via Downregulation of Genes
Joseph P. Grande, M.D., Ph.D.Mark D. Stegall, M.D.
Walter D. ParkMayo Clinic - Rochester, MN USA
METHODS
• 16 ABO-incompatible allografts studied at 3 and 12 months
RESULTS
• Circulating anti-blood group antibody and target blood group antigen demonstrated in all patients
• 13/16 grafts had normal renal function and histology
• 3 grafts with prior humoral rejection demonstrated significant glomerulopathy
METHODS• Compared five one-year protocol ABO-
compatible biopsies to four accommodated ABO-incompatible graft biopsies
• Alterations in gene expression in 440 probe sets identified– Smads– Protein tyrosine kinase– TNF– Mucin 1
• Alterations in gene expression verified by RT-PCR and/or immunohistochemistry
RESULTS
• Genes not increased in ABO-incompatible grafts– Heme oxygenase 1– Bcl-2– Bcl-XL
CONCLUSIONS
• Accommodation is present in well-functioning ABO-incompatible renal allografts
• Accommodation may involve several novel mechanisms including perturbation of signal transduction, alterations in cellular adhesion, and prevention of apoptosis
INTRODUCTION
• ABO-incompatible allografts have been used to meet donor shortage
• Refinements in immunosuppression and patient selection have increased survival of ABO-incompatible renal allografts
• Anti-donor blood group antibody usually returns and persists despite chronic immunosuppression
INTRODUCTION
• In most patients, the graft continues to function well despite the presence of antibody
• Mechanisms underlying “accommodation” are unclear
METHODS
• 16 ABO-incompatible living donor renal allografts performed between May 1999-January 2001
• Immunosuppression– Thymoglobulin antibody induction (1.5 mg/kg/d
x 10 d)– Tacrolimus (target 15 ng/dl)– Mycophenolate mofetil (2 g/d)– Prednisone (500 mg taper to 10 mg/d by 3 months)
METHODS
• Recipients of non-A2 kidneys received pre-transplant plasmaphoresis (daily x4) and splenectomy at time of transplant
• Controls consisting of 5 ABO-compatible patients, with normal three-month and one year protocol biopsies and stable function
METHODS
• Antibody titers– A1 or B blood group red cells suspended in
dilutions of recipient serum– Immediate spin assay represents IgM activity– Specimens incubated at 37° and with anti-
human globulin represents IgG activity
METHODS
• Accommodation, definition1. Detectible antidonor antibody in recipient
serum
2. Normal histology by light microscopy
3. Persistence of A or B antigen in the kidney
4. GFR >45 mL/min/1.73 m2
MICROARRAY ANALYSIS
• 16 gauge biopsies placed in RNA later (Ambien, Inc.)
• RNA extracted with TRIzol reagent (Invitrogen) core
• RNA purified using RNeasy Mini Kit (Qiagen, Inc.)
MICROARRAY ANALYSIS
• Sample quality assessed with Agilent 2100 Bioanalyzer for 18 and 28 s at RNA peaks
• Biotinylated target RNA prepared from total RNA and hybridization of cRNA to Affymetrix test 3 and U95Av2 microarrays performed in microarray core facility
STATISTICAL ANALYSIS
• Log average ratio calculated by gene shift microarray suite v4.01 (Affymetrix)
• Hybridization index: average LAR for a transcript within a group of samples HI = HIaccommodation – HIABO compatible
• Gene expression verified by RT-PCR
RESULTS
• Patient and graft survival 100% at one year
• No hyperacute or acute cellular rejection identified
• Four patients had episode of humor rejection in first month after transplant
• Responded to corticosteroids and plasmapheresis
RESULTS
• All 16 patients showed persistence of donor blood group antigen in the graft and anti-blood group antibody in circulation
• 13 patients had normal renal function and normal kidney biopsy – 7 recipients of A2 kidneys– 6 recipients of non-A2 kidneys who had
undergone splenectomy
RESULTS
• Anti-donor blood group antibody levels lower than pre-transplant levels
• Accommodated group had less IgM at 3 and 12 months than pre-transplant levels
RESULTS
• Of 12,600 genes examined by U95Av2– 4933 had HI values <1 or exhibited small
changes in expression– 440 probe sets had significant changes in
expression• 404 downregulated
• 33 upregulated
RESULTS
• Upregulated genes– Protein tyrosine kinase GFRA1– Immunoregulator MUC1
• Downregulated genes– TNF– Smad5
RESULTS
• Unable to detect– HO-1– Bcl-2– Bcl-XL– Bax
• MUC1 expression strongly positive along glomerular capillary wall
RESULTS
• Accommodation can occur over a wide range of anti-blood group antibody titers– 6 of 13 patients with anti-A/B anti-titers >1:32
had excellent graft function at one year
• Protocol biopsies of these patients were unremarkable.
MECHANISMS OF GRAFT INJURY
• Complement-mediated vascular thrombosis
• Antibody-dependent cellular cytotoxicity
• Binding of antibody to endothelial cell antigen– Endothelial cell apoptosis
ACCOMMODATION
• Recent studies suggest that some forms of accommodation are associated with induction of anti-apoptotic genes – HO-1– Bcl-XL
RESULTS
• TGF- signaling is reduced in accommodated grafts
• Smad4 HI -1.06, P = 0.022
• Smad5 HI -1.68, P = 0.014
• EGFR HI +0.63, P = 0.010
RESULTS
• Protein tyrosine kinases
• GFRA1 HI +1.45, P = 0.018– Receptor which mediates binding and
activation of RET
• PRKB HI -2.04, P = 0.003– PRKB binds cAMP
TNF FAMILY
• TNF HI -0.82, P = 0.033
• TACE HI +1.16, P = 0.044– Cleaves precursor TNF to its mature form
• TRAF6 HI -0.97, P = 0.030
TNF FAMILY
• MUC1 HI 1.18, P = 0.016– Transmembrane protein expressed on the apical
surface of ductal epithelial cells
• Involved in– Cell adhesion– Cell signaling– Immunoregulation
LIMITATIONS, MICROARRAY ANALYSIS
• Decreased sensitivity of microarrays
• Heterogeneous cell populations
• Reproducibility
SUMMARY
• Accommodation is associated with alterations in genes related to – Signal transduction– Cell-cell adhesion– T-cell activation– Prevention of apoptosis (pro-survival pathways)